title: Adjuvant radiotherapy for pediatric and young adult nonrhabdomyosarcoma soft-tissue sarcoma.
abstract: OBJECTIVE
  To evaluate the prognostic factors, outcomes, and complications in patients aged ≤30 years with resectable nonrhabdomyosarcoma soft-tissue sarcoma treated at the University of Florida with radiotherapy (RT) during a 34-year period.
  
  
  METHODS
  A total of 95 pediatric or young adult patients with nonrhabdomyosarcoma soft-tissue sarcoma were treated with curative intent with surgery and RT at the University of Florida between 1973 and 2007. The most common histologic tumor subtypes were synovial sarcoma in 22 patients, malignant fibrous histiocytoma in 19, and malignant peripheral nerve sheath tumor in 11 patients. The mean age at RT was 22 years (range, 6-30). Of the 95 patients, 73 had high-grade tumors; 45 had undergone preoperative RT and 50 postoperative RT. The prognostic factors for survival, local recurrence, and distant recurrence were analyzed.
  
  
  RESULTS
  The median follow-up was 7.2 years (range, 0.4-30.5). The actuarial 5-year local control rate was 88%. A microscopically negative margin was associated with superior local control. Although 83% of local recurrence cases initially developed in the absence of metastases, all patients with local failure ultimately died of their disease. The actuarial estimate of 5-year overall survival and disease-free survival was 65% and 63%, respectively. Of all the deaths, 92% were disease related. An early American Joint Committee on Cancer stage, tumor<8 cm, and the absence of neurovascular invasion were associated with superior disease-free survival. The National Cancer Institute Common Toxicity Criteria, version 3, Grade 3-4 treatment complication rate was 9%. No secondary malignancies were observed.
  
  
  CONCLUSIONS
  In the present large single-institution study, we found positive margins and locally advanced features to be poor prognostic factors for both local progression and survival. The results from the present study have helped to characterize the therapeutic ratio of RT in pediatric and young adult sarcoma patients and have provided a basis for identifying high-risk patients for whom treatment intensification might be justified.
authors.affiliation: Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.
authors.forename: Kristy B
authors.initials: KB
authors.lastname: Smith
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Indelicato
authors.forename: Jacquelyn A
authors.initials: JA
authors.lastname: Knapik
authors.forename: Joanne P
authors.initials: JP
authors.lastname: Lagmay
authors.forename: Christopher
authors.initials: C
authors.lastname: Morris
authors.forename: Jessica M
authors.initials: JM
authors.lastname: Kirwan
authors.forename: Robert A
authors.initials: RA
authors.lastname: Zlotecki
authors.forename: Mark T
authors.initials: MT
authors.lastname: Scarborough
authors.forename: C Parker
authors.initials: CP
authors.lastname: Gibbs
authors.forename: Robert B
authors.initials: RB
authors.lastname: Marcus
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D051677:Histiocytoma, Malignant Fibrous / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary / Q000628:therapy; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000401:mortality; D018365:Neoplasm, Residual; D018317:Nerve Sheath Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary / Q000628:therapy; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D013584:Sarcoma, Synovial / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000628:therapy; D055815:Young Adult